AR053155A1 - Derivados de 1, 2, 4 - triazinas, su preparacion, composiciones farmaceuticas que los contienen y su aplicacion en el tratamiento de enfermedades mediadas por la activacion de los receptores ppar gamma y/o alfa. - Google Patents
Derivados de 1, 2, 4 - triazinas, su preparacion, composiciones farmaceuticas que los contienen y su aplicacion en el tratamiento de enfermedades mediadas por la activacion de los receptores ppar gamma y/o alfa.Info
- Publication number
- AR053155A1 AR053155A1 ARP060100797A ARP060100797A AR053155A1 AR 053155 A1 AR053155 A1 AR 053155A1 AR P060100797 A ARP060100797 A AR P060100797A AR P060100797 A ARP060100797 A AR P060100797A AR 053155 A1 AR053155 A1 AR 053155A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- dioxo
- ethyl
- yloxy
- triazin
- Prior art date
Links
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
- 230000004913 activation Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 hydroxycarbonylvinyl Chemical group 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 abstract 1
- SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical class O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000000654 additive Chemical class 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 150000007942 carboxylates Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000002825 nitriles Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Liquid Crystal Substances (AREA)
Abstract
Derivados de 3,5-dioxo-(2H,4H)-1,2,4-triazina de la formula general (1) en los cuales R1 y R2 pueden ser idénticos o diferentes y representan un radical alquilo o alquenilo, lineal o ramificado C1-7, alquilo C1-6 substituido con grupos tales como trifluorometilo, cicloalquilo C5-6, nitrilo, alcoxicarbonilvinilo C1-4, hidroxicarbonilvinilo, alcoxicarbonilo C1-4, carboxilato, benciloxi o fenilo (ara el cual el nucleo fenilo está posiblemente sustituido con uno o más grupos tales como alquilo C1-4, alcoxi C1-4, nitro, halogeno o trifluormetilo), YR3 representa O NFR3 en el cual R3 representa H alquilo o alquenilo, lineal o ramificado C1-7, alquilo C1-6 substituido con grupos tales como trifluormetilo o fenilo (para los cuales el nucleo fenilo está posiblemente sustituido con uno o más grupos tales como alquilo C1-4, alcoxi C1-4, nitro, halogeno o trifluormetilo), Z representa un átomo de O o un átomo de C que puede estar ligado en posicion orto, meta o para sobre el grupo fenilo de formula (1); n puede estar en un rango de entre 0 a 5 cuando Z=C o de 2 a 4 cuando Z=O; X representa O o S; R4, R5, R6, R7 y R8 representan H o F; R9, R10 y R11 representa H o un grupo alquilo lineal o ramificado C1-5, así como también sales aditivas con bases farmacéuticamente aceptables, y los varios enantiomeros de los compuestos que tienen carbonos asimétricos, así como también sus mezclas en todas las porciones, incluyendo mezclas racémicas en particular. Reivindicacion 6: 2-metil- 2-(3-{3-[2-metil-3,5-dioxo-4-(4,4,4-trifluor-butil)-2,3,4,5-tetrahidro-[1,2,4]triazin-6-iloxi]-etil}-fenoxi)-propionato de etilo. Reivindicacion 7: 2-{3-[3-(4-heptil-2-metil-3,5-dioxo-2,3,4,5-tetrahidro-[1,2,4]triazin-6-iloxi)-propil]-fenoxi}-2- metil-propionato de etilo. Reivindicacion 8: 2-(3-{3-[4-heptil-3,5-dioxo-2-(4,4,4-trifluor-butil)-2,3,4,5-tetrahidro-[1,2,4]triazin-6-iloxi]-propil}-fenoxi)-2-metil-propionato de etilo. Reivindicacion 9: 2-metil-2-(3-{5-[4-metil-3,5-dioxo-2-(4,4,4- trifluor-butil)-2,3,4,5-tetrahidro-[1,2,4]triazin-6-iloxi]-pentil}-fenoxi}-propionato de etilo. Reivindicacion 10: 2-{3-[5-(2-heptil-4-metil-3,5-dioxo-2,3,4,5-tetrahidro-[1,2,4]triazin-6-iloxi)-pentil]-fenoxi}-2-metil-propionato de etilo. Reivindicacion 11: 2-{3-[5-(4-butil-2-metil-3,5-dioxo-2,3,4,5-tetrahidro-[1,2,4]triazin-6-iloxi)-pentil]-fenoxi}-2-metil-propionato de etilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0502152A FR2882750B1 (fr) | 2005-03-03 | 2005-03-03 | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053155A1 true AR053155A1 (es) | 2007-04-25 |
Family
ID=35116027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100797A AR053155A1 (es) | 2005-03-03 | 2006-03-02 | Derivados de 1, 2, 4 - triazinas, su preparacion, composiciones farmaceuticas que los contienen y su aplicacion en el tratamiento de enfermedades mediadas por la activacion de los receptores ppar gamma y/o alfa. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7713971B2 (es) |
| EP (1) | EP1856065B1 (es) |
| JP (1) | JP5269420B2 (es) |
| KR (1) | KR20070112230A (es) |
| CN (1) | CN101155790A (es) |
| AR (1) | AR053155A1 (es) |
| AT (1) | ATE448211T1 (es) |
| AU (1) | AU2006219802A1 (es) |
| BR (1) | BRPI0607567A2 (es) |
| CA (1) | CA2599848A1 (es) |
| CR (1) | CR9366A (es) |
| DE (1) | DE602006010337D1 (es) |
| ES (1) | ES2336823T3 (es) |
| FR (1) | FR2882750B1 (es) |
| IL (1) | IL185586A0 (es) |
| MA (1) | MA29343B1 (es) |
| MX (1) | MX2007010787A (es) |
| MY (1) | MY140662A (es) |
| NI (1) | NI200700224A (es) |
| NO (1) | NO20074881L (es) |
| PL (1) | PL1856065T3 (es) |
| PT (1) | PT1856065E (es) |
| RU (1) | RU2007136027A (es) |
| TN (1) | TNSN07335A1 (es) |
| TW (1) | TW200643016A (es) |
| WO (1) | WO2006092507A1 (es) |
| ZA (1) | ZA200707730B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ592057A (en) | 2008-09-05 | 2013-01-25 | Acucela Inc | Sulfur-linked compounds for treating opthalmic diseases and disorders |
| JP2013538215A (ja) | 2010-08-31 | 2013-10-10 | エスエヌユー アールアンドディービー ファウンデーション | ＰＰＡＲδアゴニストの胎児再プログラミング用途 |
| CN107074823B (zh) * | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| TWI840423B (zh) | 2018-10-12 | 2024-05-01 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| EP4028008A4 (en) | 2019-09-12 | 2023-09-13 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| EP4568664A1 (en) | 2023-04-07 | 2025-06-18 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2707294B1 (fr) | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
| UA82048C2 (uk) * | 2000-11-10 | 2008-03-11 | Эли Лилли Энд Компани | Агоністи альфа-рецепторів, активованих проліфератором пероксисом |
| GB0113233D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical compounds |
| FR2866339B1 (fr) * | 2004-02-18 | 2006-05-05 | Pf Medicament | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
-
2005
- 2005-03-03 FR FR0502152A patent/FR2882750B1/fr not_active Expired - Fee Related
-
2006
- 2006-03-02 BR BRPI0607567-3A patent/BRPI0607567A2/pt not_active IP Right Cessation
- 2006-03-02 RU RU2007136027/04A patent/RU2007136027A/ru not_active Application Discontinuation
- 2006-03-02 ES ES06726008T patent/ES2336823T3/es active Active
- 2006-03-02 JP JP2007557542A patent/JP5269420B2/ja not_active Expired - Fee Related
- 2006-03-02 EP EP06726008A patent/EP1856065B1/fr active Active
- 2006-03-02 CA CA002599848A patent/CA2599848A1/fr not_active Abandoned
- 2006-03-02 US US11/885,630 patent/US7713971B2/en not_active Expired - Fee Related
- 2006-03-02 AR ARP060100797A patent/AR053155A1/es unknown
- 2006-03-02 WO PCT/FR2006/000469 patent/WO2006092507A1/fr not_active Ceased
- 2006-03-02 KR KR1020077022414A patent/KR20070112230A/ko not_active Abandoned
- 2006-03-02 PL PL06726008T patent/PL1856065T3/pl unknown
- 2006-03-02 MX MX2007010787A patent/MX2007010787A/es active IP Right Grant
- 2006-03-02 AT AT06726008T patent/ATE448211T1/de not_active IP Right Cessation
- 2006-03-02 PT PT06726008T patent/PT1856065E/pt unknown
- 2006-03-02 TW TW095107034A patent/TW200643016A/zh unknown
- 2006-03-02 AU AU2006219802A patent/AU2006219802A1/en not_active Abandoned
- 2006-03-02 DE DE602006010337T patent/DE602006010337D1/de active Active
- 2006-03-02 CN CNA2006800114913A patent/CN101155790A/zh active Pending
- 2006-03-03 MY MYPI20060914A patent/MY140662A/en unknown
-
2007
- 2007-08-29 IL IL185586A patent/IL185586A0/en unknown
- 2007-08-30 NI NI200700224A patent/NI200700224A/es unknown
- 2007-08-31 TN TNP2007000335A patent/TNSN07335A1/fr unknown
- 2007-09-04 CR CR9366A patent/CR9366A/es not_active Application Discontinuation
- 2007-09-10 ZA ZA200707730A patent/ZA200707730B/en unknown
- 2007-09-25 MA MA30243A patent/MA29343B1/fr unknown
- 2007-09-25 NO NO20074881A patent/NO20074881L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20074881L (no) | 2007-11-27 |
| CA2599848A1 (fr) | 2006-09-08 |
| KR20070112230A (ko) | 2007-11-22 |
| NI200700224A (es) | 2008-03-27 |
| ES2336823T3 (es) | 2010-04-16 |
| TW200643016A (en) | 2006-12-16 |
| CR9366A (es) | 2008-02-12 |
| US20080167313A1 (en) | 2008-07-10 |
| EP1856065B1 (fr) | 2009-11-11 |
| PL1856065T3 (pl) | 2010-04-30 |
| JP2008531662A (ja) | 2008-08-14 |
| AU2006219802A1 (en) | 2006-09-08 |
| WO2006092507A1 (fr) | 2006-09-08 |
| EP1856065A1 (fr) | 2007-11-21 |
| IL185586A0 (en) | 2008-01-06 |
| DE602006010337D1 (de) | 2009-12-24 |
| CN101155790A (zh) | 2008-04-02 |
| ZA200707730B (en) | 2008-05-28 |
| MY140662A (en) | 2010-01-15 |
| MA29343B1 (fr) | 2008-03-03 |
| RU2007136027A (ru) | 2009-04-10 |
| US7713971B2 (en) | 2010-05-11 |
| MX2007010787A (es) | 2007-09-25 |
| FR2882750B1 (fr) | 2007-05-11 |
| WO2006092507A8 (fr) | 2007-11-01 |
| FR2882750A1 (fr) | 2006-09-08 |
| ATE448211T1 (de) | 2009-11-15 |
| PT1856065E (pt) | 2010-02-10 |
| JP5269420B2 (ja) | 2013-08-21 |
| TNSN07335A1 (fr) | 2008-12-31 |
| BRPI0607567A2 (pt) | 2011-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068479A1 (es) | (carboxilalquilenfenil) feniloxamidas, procedimiento para su preparacion y una coomposicion farmaceutica | |
| AR060990A1 (es) | Acidos carboxilicos sustituidos con fenilaminobenzoxazol y composiciones farmaceuticas que los contienen, utilizadas para el tratamiento de la diabetes | |
| AR067058A1 (es) | Oxazolidinonas sustituidas y su uso para preparar medicamentos | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR087151A1 (es) | Diaminocarboxamida y diaminocarbonitrilo pirimidinas sustituidas, sus composiciones y los metodos de tratamiento | |
| AR062109A1 (es) | Derivados sustituidos de espirocetal y uso de los mismos como farmacos terapeuticos para la diabetes. composiciones farmaceuticas. | |
| PE20091099A1 (es) | Derivados de aminobenzamida como agentes utiles para controlar parasitos animales | |
| RU2014122033A (ru) | Соединения с нематоцидной активностью | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| AR057071A1 (es) | Producto de combinacion que comprende arilpirazoles sustituidos | |
| CO6241076A2 (es) | Compuestos de benzamida y aplicaciones de los mismos | |
| ECSP11010901A (es) | Compuestos de amida útiles en terapia | |
| HRP20100541T1 (hr) | Derivati bifeniloksioctene kiseline za liječenje respiratornih bolesti | |
| AR053155A1 (es) | Derivados de 1, 2, 4 - triazinas, su preparacion, composiciones farmaceuticas que los contienen y su aplicacion en el tratamiento de enfermedades mediadas por la activacion de los receptores ppar gamma y/o alfa. | |
| AR080249A1 (es) | Compuestos en calidad de antagonistas de bradiquinina-b1 | |
| CO6260069A2 (es) | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa | |
| AR058043A1 (es) | Derivados plaguicidas de fenilamidina benciloxi y fenetil sustituidos | |
| AR077227A1 (es) | Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| ES2485867T3 (es) | Compuestos opioides de carboxamido | |
| AR084948A1 (es) | Agente antifungico topico | |
| ES2561674T3 (es) | Antagonistas de TRPV4 | |
| EA200800372A1 (ru) | Соединения и их соли, специфичные к ppar рецепторам и egf рецепторам, и их применение в области медицины | |
| AR074721A1 (es) | Derivados de 1,3 tiazol inhibidores de adn girasa y/o topoisomerasa iv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |